Abstract:
Introduction. Sodium-glucose cotransporter 2 (SGLT2) inhibitors represent a drug class
commonly used in the management of type 2 diabetes.
Aim of study. Dapagliflozin demonstrated a significant decrease in the occurrence of
cardiovascular (CV) death or hospitalization due to heart failure (HHF).
Methods and materials. Based on articles about SGLT2 inhibitors from the PubMed platform,
we selected the fundamentals of this drug's actions on human metabolism, specifically in patients
with type 2 diabetes.
Results. The studies consulted from various medical search platforms such as PubMed, Google
Scholar, etc., highlight an emphasis on examining the impact of dapagliflozin on body weight. It
was observed that this medication assists patients in reducing fat mass, contributing to as much as
two-thirds of the overall weight loss, and demonstrates a smaller waist circumference compared
to patients who were administered an add-on placebo. Dapagliflozin was orally administered to
patients once daily.
Conclusion. Real-world studies provided evidence supporting the effectiveness of dapagliflozin
in individuals with type 2 diabetes (T2D).
